Campbell & CO Investment Adviser LLC Takes $260,000 Position in MEDNAX Inc (NYSE:MD)

Campbell & CO Investment Adviser LLC purchased a new stake in shares of MEDNAX Inc (NYSE:MD) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,505 shares of the company’s stock, valued at approximately $260,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in MD. P2 Capital Partners LLC boosted its holdings in shares of MEDNAX by 96.9% during the second quarter. P2 Capital Partners LLC now owns 2,750,000 shares of the company’s stock valued at $69,383,000 after acquiring an additional 1,353,111 shares during the period. AQR Capital Management LLC boosted its holdings in shares of MEDNAX by 86.2% during the second quarter. AQR Capital Management LLC now owns 1,754,829 shares of the company’s stock valued at $43,327,000 after acquiring an additional 812,425 shares during the period. D. E. Shaw & Co. Inc. boosted its holdings in shares of MEDNAX by 20.7% during the second quarter. D. E. Shaw & Co. Inc. now owns 3,001,827 shares of the company’s stock valued at $75,736,000 after acquiring an additional 515,286 shares during the period. First Trust Advisors LP boosted its holdings in shares of MEDNAX by 40.8% during the first quarter. First Trust Advisors LP now owns 1,457,639 shares of the company’s stock valued at $39,604,000 after acquiring an additional 422,706 shares during the period. Finally, WINTON GROUP Ltd boosted its holdings in shares of MEDNAX by 79.6% during the second quarter. WINTON GROUP Ltd now owns 802,412 shares of the company’s stock valued at $20,245,000 after acquiring an additional 355,681 shares during the period. 92.27% of the stock is owned by institutional investors.

Shares of NYSE MD opened at $22.95 on Monday. MEDNAX Inc has a fifty-two week low of $19.93 and a fifty-two week high of $45.18. The firm’s 50-day simple moving average is $22.20 and its 200 day simple moving average is $24.54. The company has a quick ratio of 2.23, a current ratio of 2.23 and a debt-to-equity ratio of 0.79. The stock has a market cap of $2.00 billion, a P/E ratio of 6.54, a P/E/G ratio of 0.92 and a beta of 0.73.

MEDNAX (NYSE:MD) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.89 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.11. MEDNAX had a negative net margin of 3.53% and a positive return on equity of 9.34%. The business had revenue of $868.31 million for the quarter, compared to analysts’ expectations of $868.71 million. During the same period in the previous year, the business earned $1.07 earnings per share. The company’s revenue was up .4% on a year-over-year basis. On average, sell-side analysts anticipate that MEDNAX Inc will post 3.05 earnings per share for the current fiscal year.

In related news, Director Md Pascal J. Goldschmidt sold 5,000 shares of MEDNAX stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $20.81, for a total transaction of $104,050.00. Following the sale, the director now directly owns 15,821 shares in the company, valued at $329,235.01. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Michael Fernandez acquired 122,409 shares of the business’s stock in a transaction that occurred on Monday, August 12th. The shares were bought at an average price of $21.35 per share, for a total transaction of $2,613,432.15. Following the completion of the purchase, the director now owns 350,288 shares of the company’s stock, valued at $7,478,648.80. The disclosure for this purchase can be found here. 3.40% of the stock is owned by insiders.

MD has been the subject of several analyst reports. Credit Suisse Group reduced their price target on shares of MEDNAX from $30.00 to $28.00 and set an “outperform” rating for the company in a report on Tuesday, August 27th. Bank of America downgraded shares of MEDNAX from a “neutral” rating to an “underperform” rating and set a $19.00 price target for the company. in a report on Friday, September 6th. UBS Group reduced their price target on shares of MEDNAX from $19.00 to $18.00 and set a “sell” rating for the company in a report on Friday. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating and set a $23.00 price target for the company in a report on Monday, October 14th. Finally, BMO Capital Markets reduced their price target on shares of MEDNAX from $32.00 to $25.00 and set a “market perform” rating for the company in a report on Monday, August 5th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. MEDNAX has a consensus rating of “Hold” and a consensus price target of $27.80.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

See Also: Why do corrections happen?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.